A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3
Keywords: cD-tboc; isoflavone derivative 7-(O)-carboxymethyl daidzein conjugated to N-t-boc-hexylenediamine; DTC; differentiated thyroid carcinoma; 1.25D; 1,25 dihydroxy vitamin D3; ERs; estrogen receptors; ERα; estrogen receptor α; ERβ; estrogen receptor β; 1O